Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M-R Taskinen

Showing results (201-210 of 269) with videos related to

Pageof 27
Sort By:
Diabetes Care|January 1, 1994
Normalization of lipoprotein composition by intraperitoneal insulin in IDDM. Role of increased hepatic lipase activityG Ruotolo, M Parlavecchia, M R Taskinen, et al.
Thrombosis and Haemostasis|May 9, 2001
Effects of oral and transdermal estrogen replacement therapy on markers of coagulation, fibrinolysis, inflammation and serum lipids and lipoproteins in postmenopausal womenS Vehkavaara, A Silveira, T Hakala-Ala-Pietilä, et al.
Circulation|November 30, 2000
Differential effects of oral and transdermal estrogen replacement therapy on endothelial function in postmenopausal womenS Vehkavaara, T Hakala-Ala-Pietilä, A Virkamäki, et al.
Acta Diabetologica|December 1, 1994
Asymptomatic coronary artery disease in diabetes: relation to common risk factors, lipoproteins, apoproteins and apo E polymorphismM J Koistinen, H V Huikuri, U R Korhonen, et al.
Diabetologia|March 14, 1998
Effects of dietary cholesterol on plasma lipoproteins and their subclasses in IDDM patientsG Romano, M K Tilly-Kiesi, L Patti, et al.
International Journal of Clinical Practice|June 14, 2012
Long-term safety and efficacy of linagliptin as monotherapy or in combination with other oral glucose-lowering agents in 2121 subjects with type 2 diabetes: up to 2 years exposure in 24-week phase III trials followed by a 78-week open-label extensionR Gomis, D R Owens, M-R Taskinen, et al.
Atherosclerosis|February 13, 2001
Reduced hormone-sensitive lipase activity is not a major metabolic defect in Finnish FCHL familiesK Ylitalo, V Large, P Pajukanta, et al.
Diabetic Medicine : a Journal of the British Diabetic Association|December 1, 1994
Lipoprotein(a) in type 1 diabetic patients with renal diseaseP H Groop, G C Viberti, T G Elliott, et al.
Thrombosis and Haemostasis|April 1, 2000
Fibrinolytic proteins and progression of coronary artery disease in relation to gemfibrozil therapyA Hamsten, M Syvänne, A Silveira, et al.
Metabolism: Clinical and Experimental|September 1, 1987
Integrated study of low density lipoprotein metabolism and very low density lipoprotein metabolism in non-insulin-dependent diabetesB V Howard, W G Abbott, W F Beltz, et al.
Pageof 27

Showing results (201-210 of 269) with videos related to

Sort By:
Pageof 27
Diabetes Care|January 1, 1994
Normalization of lipoprotein composition by intraperitoneal insulin in IDDM. Role of increased hepatic lipase activityG Ruotolo, M Parlavecchia, M R Taskinen, et al.
Thrombosis and Haemostasis|May 9, 2001
Effects of oral and transdermal estrogen replacement therapy on markers of coagulation, fibrinolysis, inflammation and serum lipids and lipoproteins in postmenopausal womenS Vehkavaara, A Silveira, T Hakala-Ala-Pietilä, et al.
Circulation|November 30, 2000
Differential effects of oral and transdermal estrogen replacement therapy on endothelial function in postmenopausal womenS Vehkavaara, T Hakala-Ala-Pietilä, A Virkamäki, et al.
Acta Diabetologica|December 1, 1994
Asymptomatic coronary artery disease in diabetes: relation to common risk factors, lipoproteins, apoproteins and apo E polymorphismM J Koistinen, H V Huikuri, U R Korhonen, et al.
Diabetologia|March 14, 1998
Effects of dietary cholesterol on plasma lipoproteins and their subclasses in IDDM patientsG Romano, M K Tilly-Kiesi, L Patti, et al.
International Journal of Clinical Practice|June 14, 2012
Long-term safety and efficacy of linagliptin as monotherapy or in combination with other oral glucose-lowering agents in 2121 subjects with type 2 diabetes: up to 2 years exposure in 24-week phase III trials followed by a 78-week open-label extensionR Gomis, D R Owens, M-R Taskinen, et al.
Atherosclerosis|February 13, 2001
Reduced hormone-sensitive lipase activity is not a major metabolic defect in Finnish FCHL familiesK Ylitalo, V Large, P Pajukanta, et al.
Diabetic Medicine : a Journal of the British Diabetic Association|December 1, 1994
Lipoprotein(a) in type 1 diabetic patients with renal diseaseP H Groop, G C Viberti, T G Elliott, et al.
Thrombosis and Haemostasis|April 1, 2000
Fibrinolytic proteins and progression of coronary artery disease in relation to gemfibrozil therapyA Hamsten, M Syvänne, A Silveira, et al.
Metabolism: Clinical and Experimental|September 1, 1987
Integrated study of low density lipoprotein metabolism and very low density lipoprotein metabolism in non-insulin-dependent diabetesB V Howard, W G Abbott, W F Beltz, et al.
Pageof 27